Clinical Trials
77 trialsProgrammed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma
Sun Yat-sen University
Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
Sun Yat-sen University
Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma
Sun Yat-sen University
IC Plus Low-dose Radiation Plus Cadonilimab in LANPC
Sun Yat-sen University
(NeoScorch HN)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Invert-Prospective Phase II Randomized Trial of Involved Nodal Versus Elective Neck RadioTherapy
University of Texas Southwestern Medical Center
PEACH
Royal Marsden NHS Foundation Trust
Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC
Second Affiliated Hospital, School of Medicine, Zhejiang University
Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
Merus B.V.
Lattice-Based Radiotherapy and Chemo-Immunotherapy for Oral Cavity Squamous Cell Carcinoma
NYU Langone Health
ORATOR2
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer
Mayo Clinic
Circulating Tumor Cell Counts in Postoperative ENE-Positive Oral Cavity Cancer Patients After Adjuvant CCRT
Chang Gung Memorial Hospital
Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma
M.D. Anderson Cancer Center
Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection
M.D. Anderson Cancer Center
UPFRONT-NECK
Insel Gruppe AG, University Hospital Bern
Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers
University of Kentucky
Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer
University of California, San Diego
[18F]-AraG PET Imaging in LA HNSCC
Indiana University
OMET
Groupe Oncologie Radiotherapie Tete et Cou
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Incyte Corporation
Adjuvant vs Surgery Only in Early-stage Recurrent NPC
Eye & ENT Hospital of Fudan University
AK129 Combination Therapy for Advanced Solid Tumors
Akeso
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC
University of Colorado, Denver
Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Shandong Cancer Hospital and Institute
PembroMetaRT
UNICANCER
Addition of Aspirin to Standard of Care in Oral Cancer
Banaras Hindu University
OART
Sun Yat-sen University
Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Celldex Therapeutics
Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer
Saint Petersburg State University, Russia
Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma
Eye & ENT Hospital of Fudan University
Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Neoadjuvant Tirellizumab Combined With Chemotherapy for Early Oral Squamous Cell Carcinoma(HNC-SYSU-004)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
iCHRTL
Maria Sklodowska-Curie National Research Institute of Oncology
Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer
University of Chicago
Comparative Effectiveness Trial of Transoral Head and Neck Surgery Followed by Adjuvant Radio(Chemo)Therapy Versus Primary Radiochemotherapy for Oropharyngeal Cancer
Universitätsklinikum Hamburg-Eppendorf
A Study of Chemo +/- Low-dose Radiation as Induction Therapy in SCCHN
University of Kentucky
18F-FDG PET/CT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma
Taizhou Hospital
Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC
Sun Yat-sen University
Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck
H. Lee Moffitt Cancer Center and Research Institute
Effect of N-Acetyl Cysteine (NAC) on the Oral Microbiome
Wake Forest University Health Sciences
Optimization of Cervical Nodal CTV for Early and Medium Stage NPC
ChineseAMS
Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab in the De Novo Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPC
Eye & ENT Hospital of Fudan University
INFIELD
University of Texas Southwestern Medical Center
LM-HNSCC
ChineseAMS